Background image
Home Company Facilities

Purpose-Built, Globally Accessible

For Advanced Therapies Across the US and EU

Artis BioSolutions combines synthetic DNA manufacturing, development, analytics, and GMP manufacturing across integrated US and EU operations, supporting advanced therapy programs from starting material through clinical manufacturing. 

Boston, US  

Minutes from Boston clinical centers and designed for advanced therapy development and GMP manufacturing, the Boston facility supports integrated process development, analytical development, GMP manufacturing, and fill & finish across multiple advanced therapy modalities, including cell therapy and viral vectors.

  • 44,000 sq ft total with 14,000 sq ft GMP cleanroom space
  • 9 suites: 8 x ISO7 & 1 x ISO8
  • Large-scale GMP suite & isolator-based fill/finish
  • In-house Bioanalytical & Microbiology QC
Frame 39435 (2)

Our purpose-built advanced therapy facilities bring process development, analytics, and cGMP manufacturing together under one roof. The integrated layout supports rapid tech transfer, tight cross-functional collaboration, and continuous process learning from early development runs through GMP production.

Formulation Development
Icon Translational Research Labs
Icon Analytical Development
Modular cGMP Suites
Icon Cell Processing Suites
Icon Viral Vector Suites
Icon mRNA and LNP Suite
In-house Quality Control Labs
Icon Bioanalytical
Icon Microbiology

Bilbao, Spain  

Our EU facility, located in Technology Park of Zamudio, Basque Country, specializes in enzymatic synthetic DNA manufacturing, providing GMP-ready synthetic DNA for advanced therapies across research, development, and manufacturing applications. 

  • 37,000 sq ft production facility
  • 4 cGMP processing suites
  • 1 fill/finish suite & 8 preclinical/R&D labs
  • Gram-scale DNA production capacity
Syngoi Facility

Flexible, Modular Infrastructure

Both our Process Development Lab and GMP infrastructure are designed for flexibility from the ground up. Modular suites enable rapid configuration across programs, supporting seamless transitions from early development through clinical production.

 

By decoupling process steps and standardizing facility design, we reduce changeover time, increase operational efficiency, and adapt quickly to evolving program needs — without compromising quality or compliance.